Thryv Therapeutics, Inc.
Clinical trials sponsored by Thryv Therapeutics, Inc., explained in plain language.
-
New drug aims to tame dangerous heart rhythms in genetic disorder
Disease control Recruiting nowThis study tests whether the drug THRV-1268 can safely shorten the heart's electrical recovery time (QT interval) in people with Long QT Syndrome Type 2, a genetic condition that raises the risk of dangerous heart rhythms and sudden cardiac arrest. About 64 participants will take…
Phase: PHASE2, PHASE3 • Sponsor: Thryv Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Heart condition's hidden toll: new study asks patients about life quality
Knowledge-focused Recruiting nowThis study aims to understand how Long QT Syndrome types 2 and 3 affect the quality of life and daily burden of adults. Researchers will ask up to 200 participants to fill out questionnaires about their physical, emotional, and social well-being. No treatment is given; the goal i…
Sponsor: Thryv Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC